Stock Updates

How has Celgene Corporation:(NASDAQ:CELG) performed recently?

Celgene Corporation (NASDAQ: CELG) is a large market cap stock with a market cap of 88216.29. It is in the Biotechnology industry and sector Healthcare, with a current P/E of 47.6, a forward P/E of 16.22 and EPS of 2.38. At a stock price of 114.44 (0.93%) it has a dividend yield of *TBA.

EPS growth for the last five years have been 15.70%, more recently this last year it has grown by -18.80%. The next year growth is going to be about 22.57% and more long-term 21.87% after five years. EPS growth quarter over quarter is 72.90%. Sales growth for the past five years have been 20.60% and sales growth quarter over quarter is 20.90%.

For performance, Celgene Corporation the past week has seen a gain of -1.85%. For the last month performance for Celgene Corporation is 11.80%. While the last quarter is 13.21% and half year, 10.68%. Finally for the year, performance is -12.98%.

The 52-week high for Celgene Corporation, is at -13.70%, and for the 52-week low it comes to a value of 23.08%. The 20-day simple moving average is 8.70% and 7.36% for the 200-day simple moving average.

Volatility for the week is at 1.63%, and for the month it is 2.04%. Celgene Corporation, has a target price of 136.91.

In terms of debt, long term debt/equity is 2.58, and for total debt/equity Celgene Corporation has 0. The gross margin is 95.70%, while operating margin is 27.10%, the profit margin is 18.90%. The current ratio is 4.6 and the quick ratio is 4.4.

Insider ownership is at 0.20%, with instituitional ownership at 80.20%. Celgene Corporation has a payout ratio of 0.00%. With the total shares outstanding coming to 777.99. The shares float is 773.04, with the float short at 0.76%, with short ratio coming to 1.3.

In terms of returns, the return on assets see Celgene Corporation, get 7.20%, with its returns on investment at 8.90%. Return on equity is 35.10%. So will the investors see the target price of 136.91, reached soon?

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.


About the author

Tony Dabbs

Leave a Comment